Momenta Pays Out On Enoxaparin Shut-Out
Settles Class-Action Purchasers’ Suit
Momenta Pharmaceuticals has agreed to pay $35.0m to settle claims that it manipulated generic approval processes in the US to shut competitor Amphastar out of the US enoxaparin market.
